STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B‐cell acute lymphoblastic leukaemia

Documenti analoghi

• Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood—Are we there yet?
  di: Jan Trka, et al.
  Pubblicazione: (2024)
• Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts
  di: Neil Barrett, et al.
  Pubblicazione: (2025)
• HOPX as a tumour‐suppressive protein in T‐cell acute lymphoblastic leukaemia
  di: Chien‐Chin Lin, et al.
  Pubblicazione: (2024)
• Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer
  di: Hoda Pourhassan, et al.
  Pubblicazione: (2024)
• Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia
  di: Thomas Bauch, et al.
  Pubblicazione: (2024)